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ANALISIS HUBUNG KAIT POLIMORFISME NUKLEOTIDA TUNGGAL 
PADA GEN-GEN KEBERGANTUNGAN OPIOID DALAM KALANGAN 





Ketagihan dadah ialah gangguan kronik dan berulang yang dikaitkan dengan genetik. 
Banyak kajian telah melaporkan peranan polimorfisme nukleotida tunggal (SNP) 
terhadap pergantungan pada dadah. Antara kesemua gen tersebut, sejumlah dua belas 
(12) gen kandidat yang mempunyai kaitan dengan pergantungan pada dadah akan 
diselidiki dalam kajian ini. Gen kandidat ini ialah OPRD1 (Delta Opioid Receptor), 
OPRK1 (Kappa Opioid Receptor), COMT (Catechol – O-Methyltransferase gene), 
PDYN (Prodynorphin), DRD4 (Dopamine receptor D4), ABCB1(P glycoprotein), DUSP 
(Dual Specificity Phosphatase 27) dan rs10494334.Matlamat kajian ini adalah untuk 
menentukan kekerapan SNP rs1042114, rs702764, rs199774, rs1022563, rs910080, 
rs737866, rs10494334, rs1800955, rs1128503, rs1045642 dan rs2032582, selain 
mengkaji hubungannya dengan pergantungan pada opioid dalam kalangan lelaki Melayu 
di Malaysia. Pangkalan data genetik ini akan dibangunkan untuk rawatan berasaskan 
farmakogenetik. Peserta kajian terdiri daripada 459 orang lelaki Melayu dengan 
pergantungan pada opioid dan 543 orang lelaki Melayu yang sihat sebagai kumpulan 
kawalan. SNP digenotipkan dengan menggunakan cerakin penjenisan gen SNPTaqMan. 
Analisis statistik dilakukan dengan menggunakan perisian Golden Helix SVS untuk 
mengenal pasti pengagihan frekuensi alel dan genotip serta interaksi SNP-SNP. 
Pangkalan data dibangunkan menggunakan MySQL - iaitu pangkalan data piawai de-
 xviii 
facto yang dijalankan pada pelayan yang dilindungi. SNP rs1042114 OPRD1, rs910080 
PDYN, r1800955 DRD4, rs1128503, rs1045642, dan rs2032582 ABCB1 didapati 
mempunyai perkaitan kuat dengan ketagihan opioid pada tahap alel dengan p <0.05. 
Interaksi signifikan secara statistik juga dikenal pasti antara kebanyakan alel risiko bagi 
kesemua SNP yang dikaitkan dengan ketagihan dadah dengan polimorfisme lain yang 
diselidiki dalam kajian ini. Pangkalan data yang dihasilkan daripada penyelidikan ini 
mengenai SNP ketagihan dadah boleh digunakan oleh pegawai perubatan bagi 
memahami kesan SNP dan interaksi SNP-SNP terhadap pergantungan pada opioid untuk 























ASSOCIATION ANALYSIS OF SINGLE NUCLEOTIDE POLYMORPHISMS 





Drug addiction is a chronic and relapsing disorder is associated with genetics. 
There are many studies have been reported the roles of single nucleotide polymorphisms 
(SNPs) with drug dependence and among those, twelve (12) candidate genes that were 
associated with drug dependence will be investigated in this study. The candidate genes 
are OPRD1 (Delta Opioid Receptor), OPRK1 (Kappa Opioid Receptor), COMT 
(Catechol – O-Methyltransferase gene), PDYN (Prodynorphin), DRD4 (Dopamine 
receptor D4), ABCB1(P glycoprotein), DUSP (Dual Specificity Phosphatase 27) and 
rs10494334. The goal of this study was to determine the frequencies of these SNPs 
rs1042114, rs702764, rs199774, rs1022563, rs910080, rs737866, rs10494334, 
rs1800955, rs1128503, rs1045642, and rs2032582 and to study their association with 
opioid dependence in Malay males in Malaysian population. This genetic database will 
be established for pharmacogenetics-based treatment. Research participants were 459 
Malay males with opioid dependence and 543 healthy Malay males as controls. SNPs 
were genotyped using TaqMan SNP genotyping assay. Statistical analysis was 
performed using Golden Helix SVS software suite to identify the distribution of allele 
and genotype frequencies and SNP–SNP interactions. Database was developed using 
MySQL - the de-facto standard database that runs on a protected server. SNPs 
rs1042114 of OPRD1, rs910080 of PDYN, r1800955 of DRD4, rs1128503, rs1045642, 
 xx 
and rs2032582 of ABCB1 were strongly associated with opioid addiction at allelic level 
with p<0.05. A statistically significant interaction was also identified between most of 
the risk alleles of all the SNPs associated with drug addictions with other polymorphism 
studied in this research. The database established on drug addiction SNPs from this 
research will be useful for clinicians in the understanding of the effects of SNPs and the 
SNP–SNP interaction on opioid dependence to treat the drug dependence patients 
effectively without adverse drug responses.  
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CHAPTER 1: INTRODUCTION 
 
1.1 Drug Addiction 
  
Drug addiction is a chronic, relapsing brain disease, characterized by compulsive 
drug seeking behavior with strong genetic, sociocultural and neurodevelopment 
component. Despite the harmful consequences (Kreek et al., 2005b) and a major 
contributor to the global burden of disease worldwide (Degenhardt et al., 2013) an 
estimated 17 million people are afflicted with drug use disorder. Brain images from drug 
addicts have shown physical changes especially in the areas of decision making, 
judgment, learning, memory and behavioral control, which explains the compulsive drug 
seeking behavior among addicts (Fowler et al., 2007). Each drug binds to its protein 
target in the brain and elicits a combination of behavioral and physiological effects once 
it is administrated. Current evidence shows drug abuse exerts their reinforcing effects by 
activating, reward circuits that promote repeated drug use which eventually leads to 
addiction (Nestler, 2005). Drug addiction affects all segments of society in many 
countries, most importantly it destroys the world‘s most valuable asset, the youth. It 
destroys lives, communities, stability of nations and finally the dignity and hope of 
millions of people around the globe.  
 
According to The World Drug Report (2017), published by United Nations 
Office on Drug and Crime (UNODC), in 2015 the global estimate of annual illicit drug 
use prevalence was at 5% of the global adult population. Amongst them, almost 12 
million people inject drugs and out of this number, over 13% of people (or 1.6 million) 
who inject drugs are living with AIDS and 50% (6.1 million) are with hepatitis C. 
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Higher percentage of death were reported from Hepatitis C than HIV. According to the 
report, opioid was the top most common drug associated with fatal and non-fatal over 
dose (World Drug Report., 2017).  
 
Many individuals are self-exposed to drug and many continue to use them on an 
occasional or even on regular basis. However, only some individuals develop specific 
addictions and vulnerability to addiction differs from person to person (Gerrits et al., 
2003). Even after a prolonged period of abstinence, an individual can return to use drugs 
due to cravings and a desire to experience the enhancing effects of substance abuse 
(Markou et al., 1993, McLellan et al., 2000).   
 
No single factor determines an individual tendency to be addicted to drugs, 
however, it is postulated that at least three different categories of factors may contribute 
to the vulnerability of developing a specific addiction. The first category is the 
environmental factors which include events during childhood and adolescence, peer 
pressure and self-exposure to the drug. The second category is drug induced factors, 
leading to a variety of molecular neurobiological changes, which cause altered behaviour 
(Kreek et al., 2005a, Kreek & LaForge, 2007). 
 
The third category is genetics; several studies have suggested that illicit drug 
abuse and dependence are also under a significant genetic influence. Heritability studies 
put the estimated range at 45% – 79% among drug dependence (Tsuang et al., 1998, 
Kendler et al., 2003, Agrawal et al., 2006).  
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1.2 Global Epidemiological Data of Drug Addiction 
1.2.1 America 
 
It is estimated around 47.7 million people in the US, aged 12 years or older used 
illicit drugs or misused prescription drugs, which includes the use of marijuana, cocaine, 
heroin, hallucinogens, inhalants, or methamphetamine, and the misuse of prescription 
drugs. Estimated rates of use of illicit drugs in the past year by drug type were: 0.3 per 
100 persons for heroin, 1.8 for cocaine, and 0.6 for methamphetamine (International 
Narcotic Control Strategy., 2017). Estimated rates for prescription drug misuse by drug 
type were: 4.7 per 100 persons for prescription pain relievers, 2.3 for tranquilizers, 2.0 
for stimulants, and 0.6 for sedatives (Matsson et al., 2017, CL et al., 2017). 
 
Marijuana is the most commonly used illicit drug, however 11.8 million people 
misuse opioid that is about 4.4% of the total population. It was reported that the number 
of opioid use increased 2.35 fold from 2002 – 2016, similarly number of deaths due to 
higher dosage opioid increased 6.33 fold (533%) from 2001 – 2016 (SAMHSA., 2017). 
Most of the opioid addicts were aged 45- 54 years (2016). Another study also reported 
that usage of heroin steadily is increasing since 2007 (Merikangas & McClair, 2012) in 
the US, this is due to the increase in misuse of heroin as pain reliever which is easily 
available and cheaper (Cicero et al., 2012). 
 
1.2.2 Europe 
More than 4% of the population is affected by alcohol or drug dependence 
(Wittchen et al., 2011). European Drug Report issued by European Monitoring Centre 
 24 
for Drugs and Drug Addiction indicated that one quarter of European Unions (EU) 
populations had used illegal drugs. About 23.5 million people in the age group of 15-64 
years old were involved in cannabis abuse, cocaine 3.5 million, MDMA 2.7 million and 
Amphetamine 1.8 million. The opioid abuse is only 1.3 million and 79% of deaths due to 
the drug over dose are caused by opioid abuse, with the mean age of 38 years. Heroin is 
the most common opioid in the European Drug Market, originating from Iran or Pakistan 
(European Drug Report., 2017) 
  
1.2.3 Africa 
Drug abuse is a major problem in South Africa, and shows an increase in 2016, 
where South Africa is the largest market for illicit drugs within sub-Saharan Africa and a 
trans-shipment point for cocaine and heroin (International Narcotic Control Strategy., 
2017).  
 
Large quantities of heroin started arriving on the eastern coast of Africa in the 
late 1990s when smugglers switched from their traditional overland routes from Asia to 
the sea route across the Indian Ocean (2013). 
 
 Cannabis is the most commonly used illicit drug in South Africa, it is also a large 
source of herbal cannabis for the United Kingdom and continental Europe. Recently, 
South African police seized approximately $4.8 million worth of heroin from a Pakistani 
national believed to be part of an international syndicate (World Drug Report., 2017). 
Drug abuse is currently costing around 20 billion a year for the South African 
government and in future, it can be the biggest threat to the government. It is also 
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reported that 60% of the crime is related to drug abuse (World Drug Report., 2017). In 
2014, South Africa initiated a long-term project with U.S. support to further 
professionalize all substance use treatment staff in the country through the dissemination 
of U.S.-developed curriculum and international credentialing through the Colombo 
Plan‘s International Centre for Certification and Education of Addiction Professionals 
(International Narcotic Control Strategy., 2017).  
 
1.2.4 Asia 
In many Asian countries, the increased availability and variety of drugs such as 
heroin, cannabis, cocaine and amphetamines has led to a high prevalence of drug abuse. 
It is noted that India‘s geographic location makes it an attractive transhipment area for 
narcotics and there is evidence that in the northern part of India opium poppy is grown 
illicitly. The  National Household Survey reported alcohol (21.4%) as the primary 
substance used followed by cannabis (3.0%) and opioids (0.7%) (Dhawan et al., 2017b). 
However, it is reported that India is authorized by the international community and the 
United Nations to produce licit opium for pharmaceutical uses, and these pharmaceutical 
items and precursor chemicals are vulnerable to diversion for illicit use. There is a high 
demand for methamphetamine, the increased profitability from the manufacturing and 
distribution of methamphetamine has transformed India into a significant precursor 
chemical source and supply warehouse (World Drug Report., 2017). According to the 
Indian Ministry of Home Affairs Annual Report 2013-2014, the Government of India 
seized 1,412 kilograms (kg) of heroin; 2,372 kg of opium; 47 kg of cocaine; 3,205 kg of 
Methaqualone; 68 kg of Amphetamines; 37,466,812 tablets of Psychotropic Substances; 
1,356 kg of Ketamine; and 6,935 kg of Ephedrine and Pseudo-Ephedrine(World Drug 
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Report., 2017). India has one of the highest proportions of children and adolescents 
involved in substance abuse aged <18 years which is about 45% of the population and  
5–19 years 35.3% of the population (Dhawan et al., 2017a). It is  reported that the 
estimated number of 177,000 adults are injection drug users (IDUs) (Dhawan et al., 
2016). It is also reported that abuse onset of IDU typically occurs in adulthood after 20 
years of age, with a gradual progression from licit, gateway drugs in early adolescence to 
illicit substances (Solomon et al., 2010). India observed the United Nations sponsored 
International Day Against Drug Abuse and Illicit Trafficking on June 26, 2014, with 
programs focusing on raising awareness of the harmful effects of drug abuse. India had 
enhanced its law enforcement capacity through training to enforcement officers 
(International Narcotic Control Strategy., 2017).  
 
 Indonesia is also a destination country for illegal drugs especially for cannabis, 
methamphetamine, and heroin. It is reported that trafficking of methamphetamine and 
other synthetic drugs into Indonesia had increased in 2014 and heroin trafficking 
remained the same throughout the years. Cannabis is the most widely used drug in 
Indonesia and second highest is methamphetamine which is smuggled in through Iran, 
whereas heroin smuggled from Southwest Asia. There are estimated 4.7 million of drug 
users in Indonesia, the statistical analysis showed that 22% of the users are students and 
the most widely used narcotics are cannabis, methamphetamine and ecstasy. There is an 
increase in the drug use in the year 2014 although National Narcotics Board had a lot of 
outreach programs for the community (International Narcotic Control Strategy., 2017). 
The current government response to the ‗national drug emergency‘ is dominated by 
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criminalizing substance use disorders (SUDs) which is ineffective. Interventions are now  
focusing more evidenced-based approaches to SUDs in Indonesia (Ayu et al., 2016). 
 
It is well known that Pakistan is one of the world‘s top transit corridors for 
opiates and cannabis, which is trafficked through the countries from borders with 
Afghanistan. It is reported that around 40% of drugs like heroin and marijuana from 
Afghanistan are routed through Pakistan to China, Africa and Europe. Poppy cultivation 
had also increased in Pakistan in 2014. Pakistan also a major transit country for 
precursor chemicals used to produce heroin and methamphetamine. In 2013, UNODC 
released the results that Pakistan is a home to 6.5 million drug users who consume 59 
metric ton of heroin and cannabis annually. In 2014 it was estimated that there are 
actually 6.7 million drug users, more than 3% of the country‘s population and most of 
the drug users are aged 15 to 64 (World Drug Report., 2017). A recent study conducted 
in Pakistan showed that out of 119 participants, around 71.4% were 15-35 years, 68.1% 
below secondary education and single (51.3%) and unemployed (44.5%) participants 
were at the greatest risk of using drugs. The data showed that majority of the drug 
dependence started as recreation (37%), curiosity (34.5%), and due to life changing 
events (14.3%) (Batool et al., 2017). It is reported that Pakistan lacks the capacity to 
treat drug addiction and educate the community. In 2014, Pakistan intensified efforts to 
raise public awareness about drug abuse (International Narcotic Control Strategy., 2017).  
 
Methamphetamine or locally known as ―shabu,‖ in Philippines has been the 
primary drug consumed by the locals. Philippine authorities conducted several drug 
seizures and seized 660 kilograms (kg) of methamphetamine. It is reported that Chinese 
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drug trafficking organizations dominate the methamphetamine trade in the Philippines. 
The Philippine government conducting a lot of education programs aimed at promoting 
self-awareness (International Narcotic Control Strategy., 2017).  
 
 The national household survey showed that 3.5 million people had experienced 
at least one kind of illicit drug use in their lifetime and most of them aged between 12 
and 65 years (National Survey., 2012). The country is mainly used as a trans-shipment 
point for trafficking to the international market. In 2014, Thai authorities seized large 
quantities of heroin, cocaine, MDMA (ecstasy), crystal methamphetamine, and 
methamphetamine tablets (―yaa-baa‖). It is noted that in Thailand, there are no 
significant quantities of opiates, synthetic or other drugs cultivated or produced in 2014. 
However, in 2014 the authorities seized 210.22 kilograms (kg) of heroin, but there was a 
decline from 2013 (784.6 kg of heroin for the year) but an increase in comparison to 
2012 (127.5 kg for the year). Thailand conducts demand reduction programs, which 
includes drug addiction prevention programs with treatment for addicts. It is also noted 
various therapeutic camps have been provided throughout the country (National Survey., 
2012). It is reported that early adolescent sexual debut is linked to substance abuse, 
suggesting that associated factors need to be targeted to prevent early sexual initiation. 
These behaviours, along with drug use might persist into young adulthood, bringing the 
additional risk of contracting and transmitting HIV. However, further research is 
warranted which examines these factors to provide in-depth understanding (Thepthien et 
al., 2016). In Thailand, the drug treatment programs have gained over 700,000 drug 
addicts since the government announced its counter-narcotics priorities in September 
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2011 (International Narcotic Control Strategy., 2017). Therefore, they are in urgent need 
of more intensive and targeted interventions.  
 
China is a major producer of synthetic drugs and drug precursor chemicals; it is 
considered a significant destination and transit country for illicit drugs. According to 
China‘s National Narcotics Control Commission 2014 Annual Report on Drug Control 
in China, heroin is the most abused drug in China followed by synthetic drugs such as 
ketamine, methamphetamine, and other amphetamine-type stimulants (ATS). Heroin is 
smuggled into China from Burma, Laos, Vietnam, Afghanistan, Tajikistan, and Pakistan. 
Methamphetamine and other ATS drugs manufactured in Burma also enter China from 
the ―Golden Triangle‖ region (Burma, Laos, Thailand), and Vietnam(World Drug 
Report., 2017).The government has a lot of outreach program to raise awareness of the 
negative health effects of drug abuse and reduce the demand for drugs (International 
Narcotic Control Strategy., 2017).  
 
1.2.5 Drug addiction in Malaysia 
Drug addiction has been prevalent in Malaysia since the 19th century, and in the 
early 20th century, the main drug of abuse was opium, which was abused by Chinese 
and Indian immigrant laborers who were introduced by British colonialists to work in 
Malaya (Noorzurani et al., 2008). In 1970s heroin became the most abused substance of 
among Malays who is the main ethnic group in Malaysia compared to other ethnic 
groups and by 1980s heroin abuse among Malaysian youth was a national crisis (Rusdi 
A, 2008, Noorzurani et al., 2008).  Illicit drugs are smuggled into Malaysia from the 
golden triangle area (borders of Thailand, Laos and Myanmar) as well as Iran, Nigeria 
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and India. Most of these countries use Malaysia as a drug trafficking hub. There is no 
notable cultivation of illicit drug crops in Malaysia (International Narcotic Control 
Strategy., 2017).  
 
It was reported that the cumulative number of registered people who experienced 
problems with substance use in Malaysia between 1988 and 2006 was 300%, 241%, and 
60.7% of these were opioid misusers and an increase in HIV cases due to needle sharing 
(MyHealth., 2016). Studies have shown that between 2010 and 2015, there were 127606 
registered drug addicts in Malaysia. In 2015, 26668 drug addicts were reported and there 
were only 21777 in 2014 (Table 1.1). In 2015, new addicts comprised 77% of the total 
addicts registered while 23% were relapse cases. Majority of the registered addicts were 
male (98%). Statistics also indicated that 80% of the addicts are Malays, 8% Chinese, 
8% Indian and 4% were others. Most of them fall in the 20 – 39 age group, about 
69.09%, majority of drug abusers were labourers (21%) and part time worker (27%) and 
followed by jobless 14%.  
 
Drug addiction also correlates with the education background. The data showed 
that 20% of addicts were either not educated or having only primary level school 
education or were SRP/PMR dropouts. Around 84.1% of them were SRP/PMR or SPM 
leavers and only 4% have got tertiary education. It is reported that 61% of drug addicts 
were influenced by friends and in terms of type of drug being abused in the country. 
Heroin continues to be the main drug being abused by Malaysian; constituting 61%, 
followed by Methamphetamine 30%, Ganja 5% and Ecstasy and Amphetamine 5%. The 
usage of heroin had increased from 49% in 2010 to 75% in 2013, 68% in 2014 and drop 
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to 60% in 2015. It is also noted that in 2014, RM 26.405 billion heroin was seized by the 
Malaysian authority, it shows that there is a drastic change in the demand of heroin 
among Malaysia addicts (World Drug Report., 2017).  
 
Since its implementation, methadone treatment has successfully reduced the 
prevalence of drug dependence and HIV infection among drug users in Malaysia from 
74.7% in 2000 to 19.3% by December 2014 (Annual Report., 2014). Latest report 
demonstrated the effectiveness of methadone treatment in reducing heroin dependence 
and HIV infections as well as in improving social dependence (Ali et al., 2017) 
 
Table 1.1: Number of drug addicts reported in 2015 and 2016 
Status 2014 2015 
Difference 
2014/2015 
New addicts 13605 20289 +32.9% 
Relapse 8172 6379 +21.9% 
Total addicts 21777 26668 +18.3% 
Adapted from: Agensi Anti Dadah Kebangsaan (AADK) report 2017 
 
1.3 Molecular Basis of Addiction 
Heredity is a major risk of addiction; research had shown that 40-60% of 
addiction risk is attributable to the genetic factor, addiction genes and biological 
differences that make someone more or less vulnerable to addiction (Nestler, 2000). 
Several methods were used to study the influence of genetic on addiction, such as 
family, twin and animal studies. Twin studies revealed that familial aggregation of 
addiction was influenced by genetic factors (Agrawal & Lynskey, 2008), due to the 
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segregating genes that are shared by the twins. It is also influenced by age and other 
exposure (Agrawal et al., 2012). Substance related addiction is ranked very low at a 
young age and increases during adolescence and adulthood (Kendler et al., 2008). The 
latest report by corroborating previous findings found substance use is moderately high 
from early adolescences into young adulthood (Waaktaar et al., 2017) and it is supported 
by genetic studies (Palmer et al., 2015). Animal study is crucial in understanding the 
biology and pathophysiology of addiction. Knockout mice targeting each gene of a 
system have been created two decades ago, mutant mice represent a unique tool to test 
specific role of each addiction gene. In contrast to clinical studies, the subjects can be 
controlled according to the study need (Becker et al., 2002, Charbogne et al., 2014). 
Behavioural testing in mice is limited, however new methods or models are being 
improvised to characterize the addiction studies better. This is because addiction is a 
complex trait and thus a single gene defect might produce a relatively small effect which 
would be difficult to be detected experimentally (Nestler, 2000).  
 
Although a hereditary basis for addiction has been established, the specific gene 
involved in the etiology of these disorders has not been well defined. Researchers have 
hypothesized that specific combinations of alleles of specific genes may result in innate 
differences in phenotypic expression of cellular or physiological systems known to be 
important in mediating the responses of drugs abuse (Kreek, 2000). Other studies have 
shown that opiates, cocaine, cannabis, amphetamine, alcohol and nicotine, profoundly 
alter physiological and cellular systems. These changes are specific to the route and 
pattern of administration and length of time exposure (LaForge et al., 2000, Agrawal & 
Lynskey, 2008, Kendler & Myers, 2015). 
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Some of the induced alterations in the gene may be long lasting or even 
permanent. Therefore, cellular or physiological systems that show alterations in response 
to substances of abuse might show higher or lower expression of the receptor which is 
postulated by genetic differences from polymorphisms (LaForge et al., 2000, Sagheddu 
& Melis, 2015). These may also underlie the development of substance abuse 
susceptibility (Kreek et al., 2005a, Sweatt, 2016). 
 
A growing number of genes are significantly associated with addiction. In fact, 
research shows that few selected genes from various populations are likely to be 
involved in contributing to vulnerability to drugs, alcohol and nicotine addiction (Kreek 
et al., 2002, Volkow et al., 2012, Pandey et al., 2017). 
 
1.3.1 Molecular basis of alcoholism  
Alcohol is unique among substance abuse drugs, as it is a natural by-product of 
fermentation (Marugame et al., 2007), it has an estimated heritability of 50 % -70% 
varies with diagnostic criteria, population and gender (Tyndale, 2003, Ducci & 
Goldman, 2012). Researchers have investigated the genetic components by studying 
population of a family and inheritance of alcoholism among twins. Family and twin 
studies have supported the conclusion that the proportions of risk for this disorder are 
explained by genes which are the heritability. Twin studies are expected to have a 
similar history for developing alcoholism between the twins due to the similar genetic 
expression. Thus, it is concluded that genetic makeup of each individual can accelerate 
to addiction (Heath et al., 1997, Prescott & Kendler, 1999, Kendler et al., 2003).    
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Alcohol metabolism and the rate of its degradation products are important to 
determine its physiological effects. The primary pathway involves the conversion of 
ethanol to acetaldehyde plays a major role in mediating aversive and rewarding effects 
of ethanol. Acetaldehyde is oxidized further to acetate by aldehyde dehydrogenase. The 
key enzymes involved in alcohol metabolism are ADH and ALDH (Thomasson et al., 
1995, Chen et al., 1999).  
 
It is reported that alcoholism is less common in East Asian and Polynesian 
populations than in European populations, due to protective ADH and ALDH alleles 
(Chambers et al., 2002, Gelernter et al., 2014, Galinsky et al., 2016). ADH1B*3 allele 
reveals a higher activity of ethanol oxidation and also reported to have a protective effect 
against the risk of alcohol dependence (Edenberg & Foroud, 2006). Similarly,  
ADH1B*2 is a proactive allele, it is reported to be lower among alcohol dependence 
(Whitfield, 2002, Konishi et al., 2004, Higuchi et al., 2004, Bierut et al., 2012), this is a 
result of faster aldehyde production which might lead to unpleasant alcohol reaction. It is 
also recognized that ADH1B locus is under strong selection in East Asians and a study 
showed an independent evolution of the same locus also in Europeans (Galinsky et al., 
2016). This functional variant is negatively associated with drinking behaviours, mainly 
in European populations (Gelernter et al., 2014).  
 
Allele ADH1C*2 of ADH1C gene was reported to have a higher risk of alcohol 
dependence (Mulligan et al., 2003, Konishi et al., 2004, Zintzaras et al., 2006, Li et al., 
2012a). Allele ALDH2*2 from ALDH gene also lacks of activity to catalyse 
acetaldehyde, it is found in East Asian population it causes high concentration of 
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acetaldehyde after drinking alcohol and serious adverse effect reaction facial flushing, 
hypotension, headaches and nausea (Yoshida, 1992, Chen et al., 1999) An alcoholic with 
inactive ALDH2*2 have higher novelty seeking (Marugame et al., 2007). 
 
Polymorphisms in two other enzymes, ALDH1A1 (Lind et al., 2008, Sherva et 
al., 2009) and ALDH1B1 (Linneberg et al., 2010,), have also been associated with 
alcohol consumption in Finnish, European American, European, Indo Trinidadian and 
Danish populations, respectively. Minor alleles at ADH1B (i.e., rs1229984 and 
rs2066702) are associated with lower levels of drinking (Xu et al, 2015). Consistent with 
the genetic associations, these variants increase the alcohol oxidization rate, raising 
acetaldehyde levels and its related aversive symptoms, including facial flushing, nausea, 
headache, and tachycardia (Edenberg, 2007).  
 
It is also noted that ALDH rs672 another variant which very rare or absent in 
non-Asian population is negatively associated with alcohol use behaviours in Asian 
(Quillen et al., 2014). This variant causes a lack of acetaldehyde metabolism (Peng et al., 
2014), which will produce an accumulation of acetaldehyde which will cause adverse 
effect reaction.  
 
Human genetic studies have identified many other polymorphisms associated 
with alcohol dependence in genes that comprise various neurotransmitter-signalling 
pathways. This is including dopaminergic including Monoamine Oxidase A (MAOA) 
Catechol – O- Methyltranferase (COMT), Dopamine Receptor D2 (DRD2), Ankyrin 
Repeat and Kinase Domain 1(ANKK1) Tetratricopeptide Repeat Domain(TTC12) and 
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Neural Cell Adhesion Molecule 1 (NCAM1) (Köhnke et al., 2005, Tikkanen et al., 2009, 
Hendershot, 2011). 
 
 Serotonin Transporter Protein (5-HTT), Solute Carrier Family 6 Member 4 
(SLC6A4) 5 Hydroxtryptamine Receptor 3A (HTR3A), 5 Hydroxtryptamine Receptor 3B 
(HTR3B and 5 Hydroxtryptamine Receptor 1B (HTR1B); (Cao et al., 2011, Seneviratne 
et al., 2013). GABAergic gene (Gamma Aminobutyric) (e.g., Gamma Aminobutyric 
Acid Type A Receptor Alpha 1 (GABRA1), Gamma Aminobutyric Acid Type A 
Receptor Alpha 2 (GABRA2) and Gamma Aminobutyric Acid Type A Receptor Gamma 
1 (GABRG1); (Covault et al., 2004, Lappalainen et al., 2005, Agrawal & Lynskey, 2006, 
Dick et al., 2006b, Dick et al., 2006a, Covault et al., 2008, Enoch, 2008, Ittiwut et al., 
2012). The opioid receptors Opioid Receptor Mu 1 (OPRM1), Opioid Receptor Delta 
1(OPRD1) and Opioid Receptor Kappa 1 (OPRK1) (Ray & Hutchison, 2004, Zhang et 
al., 2008a, Xuei et al., 2006) and tachykinin receptor 3 (Foroud et al., 2008).  
 
1.3.2 Molecular basis of smoking 
It is estimated around 7 million smokers in the world today and most of them 
start smoking before the age of 18. Around 47.5% were male smokers compared to 
female. It is the cause of 6 million deaths around the world today(WHO report., 2017). 
Studies had shown that genetic factors do contribute to smoking from initiation to 
dependence to smoking (Bierut, 2011). Heritability estimates vary in each study, 
adolescent twins smoking behaviour ranges from 15% to 86%, population based twin 
studies provided evidence that genetic plays a larger role in smoking behaviour by late 
adolescence (Karp et al., 2005, Kendler et al., 2008, Do et al., 2015). 
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 Several large Genome Wide Association Study (GWAS) of smoking quantity 
identified associations with genetic variants in the nicotinic acetylcholine receptor 
CHRNA5-CHRNA3-CHRNB4 subunit cluster on chromosome 15q25.1 in populations of 
European ancestry (Thorgeirsson et al., 2010, Furberg et al., 2010). A study by Saccone 
and colleagues observed that the non-synonymous SNP rs16969968 in exon 5 of 
CHRNA5 has consistent effects on the risk for nicotine dependence in both European and 
African populations, despite a large difference in allele frequency for the SNP (Saccone 
et al., 2009a). Some studies identified few other SNPs from this cluster, rs578776 in the 
3′ untranslated region of CHRNA3 that has low linkage disequilibrium with rs16969968 
is associated with smoking dependence in European Americans but not in African 
Americans (Chen et al., 2012).The SNP in CHRNA5, rs588765, confers a protective 
effect for smoking dependence in populations of European descent (Saccone et al., 
2009b, Wang et al., 2009). A comprehensive meta-analysis confirmed that these loci in 
nicotinic receptor gene affect smoking dependence (Wang et al., 2009).  
 
The main enzyme implicated in nicotine metabolism is CYP2A6 a polymorphic 
enzyme gene (Hukkanen et al., 2005). Single nucleotide polymorphism (SNP) in this 
gene highly polymorphic and generate isoforms. It causes variation in enzymatic activity 
therefore the concentration of nicotine also varies among individuals (Malaiyandi et al., 
2005). A number of studies have reported the association between reduced or absent 
CYP2A6 enzyme activity and lower risk of smoking, including decreased cigarette 
consumption, smoking intensity, and withdrawal symptoms; shorter smoking duration; 
and increased cessation (Malaiyandi et al., 2006, Thorgeirsson et al., 2010, Liu et al., 
2011, Pan et al., 2015). However, some studies have failed to detect any association 
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between CYP2A6 variation and smoking addiction, which is an active smoking (London 
et al., 1999, Schulz et al., 2001, Tanner et al., 2017).  
 
Some genetic studies of smoking dependence have successfully identified risk 
factor for addiction using both GWAS and candidate gene approaches. However, these 
associated genetic factors explain only a small percentage of the variance in smoking 
dependence, indicating that further research to detect other genetic factors influencing 
smoking is warranted. 
 
1.3.3 Molecular basis and drug addiction 
Drug addiction is a chronic relapsing disease of the brain caused by drug-induced 
direct effects and persisting neuroadaptations at the epigenetic, mRNA, neuropeptide, 
neurotransmitter, or protein levels (Kreek et al., 2005a, Kreek et al., 2012). The 
identification of specific genes and functional loci moderating vulnerability has been 
challenging because it involves changes in anatomy, function, cellular and molecular 
neuroadaptations (Hyman & Malenka, 2001). 
 
Many genes show significant association or display evidence of linkage with 
drug addiction for several decades using specific molecular genetic approaches like 
genetic animal model, candidate gene screening, genome wide association and genome 
wide linkage analysis (Li & Burmeister, 2009). Significant progress has been made to 
identify susceptibility genes for addiction however, only a small subset of these genes 
has a polymorphism for which an alteration in function has been involved in 
susceptibility (Tsuang et al., 1998, Kendler et al., 1999, Kendler et al., 2003, Kendler & 
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Myers, 2015). The implication of epistatic factors, epigenetic changes and gene–
environment interactions make this task even more challenging. Translational and 
reverse translational research methods will be useful tools for a better understanding of 
the impact of gene variants on biological networks involved in addiction (Bühler et al., 
2015). Other than that it is always difficult to collect larger sample size for substance 
abuse, it is noted that large sample will achieve the level of statistical power required 
and will provide needed results on genetic influence on addiction (Kalsi et al., 2016). 
 
  Identification of specific genes conveying increased risks not only for 
understanding the causes and potential treatments for disease, but also for increasing our 
understanding of how genetic and environmental risks interact to shape liability to 
addiction. It is noted that addiction involves a wide range of genes; there is more than 
one gene responsible for addiction. It is complicated mechanisms, any individual 
technology platform or study may be limited or biased (Goldman et al., 2005). There is a 
need to combine data across technology platforms and studies that may complement one 
another. The resultant gene list, in a database with additional functional information, 
definitely will be a valuable resource for the community. Systematic and statistical 
analysis of the genes and the underlying pathways may provide a complete picture of the 










The Kappa opioid receptor OPRK1 gene encodes KOP-r and is located on 
chromosome 8q11.2. It is found in the mesolimbic pathway, the binding ligand is 
dynorphin derived from prodynorphin were reported to inhibit dopamine neurons of the 
mesolimbic system, reduces dopaminergic tone in the striatum causes dysphoric and 
adverse effect (Shippenberg & Herz, 1986, Herz, 1998, Yuferov et al., 2010). It plays an 
interesting role in addiction of drug abuse and other rewarding stimuli because it is 
considered counter the modulatory mechanism of the brain, it directly or indirectly 
induced dopaminergic stimulation (Kreek et al., 2005a, Kreek & LaForge, 2007).  
Therefore KOR agonist may be potential therapeutic agents for the treatment of drug 
addiction (Shippenberg & Rea, 1997). Several SNPs in the human OPRK1 gene have 
been reported, which are associated with drug addiction. In Western European, heroin 
dependent was genotyped for rs1051660, there was a significant association with drug 
dependent (Gerra et al., 2007). Similar results were reported among African American, 
Caucasian, Hispanic and Asian American (Yuferov et al., 2010). However, in contrary a 
large haplotype study by Zhang et al, 2008 showed no significant association among 
European American opioid dependence and control group (Zhang et al., 2008a). A study 
by Xu.S and colleagues proved that rs6989250 of OPRK1 gene also associated with 
greater subsequent cocaine relapse risk (Xu et al., 2013) it is suggesting inter population 
variation. There is also an association with drug withdrawal symptoms from the variants 
of OPRK1 such as rs7832417, rs1698853, rs702764 and rs7817710 (Wang et al., 2014) 
and also with variant rs6473797 (Jones et al., 2016). There may a significant influence of 
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genetic and drug withdrawal biochemical mechanism which needs further investigation. 
The ability to predict which individual may experience greater drug withdrawal 
symptoms may increase the success rate of a treatment.  
 
1.4.2 OPRD1 
The OPRD1 gene encodes the δ-opioid receptor (DOR) is located on 
chromosome 1p34, a G-protein-coupled receptor that regulates reward effects in the 
brain through activation of downstream MAP kinase pathways (Herz, 1998), which 
has enkephalins as its endogenous ligands. The Delta Opioid Receptor (DOR) functions 
in nociceptive responses but has also been shown to be involved in modulating the 
effects of Mu opioid receptor (MOR) directed compounds. Mice with targeted deletion 
of the OPRD1 gene do not develop tolerance to the analgesic effects of morphine, 
although still becoming physically dependent on the drug (Zhu et al., 1999, Filliol et al., 
2000). DOR plays an important role in the development of opioid tolerance (Daniels et 
al. 2005) and is involved in the rewarding and analgesic effects of opioids (Le Merrer et 
al., 2009). The Delta opioid receptor also becomes functional in the maintenance of 
opioid rewarding properties after prolonged exposure to opiates (Hack et al., 2005, Ma et 
al., 2006). Many SNPs in the OPRD1 gene have been defined (Mayer et al., 1997, 
Gelernter & Kranzler, 2000) however only a few association studies on substance 
dependence were conducted between variations of OPRD1 SNPs. A study was 
conducted among German Caucasians with heroin addiction, a significant association 
was reported for C921T (rs2234918) (Mayer et al., 1997). 
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 Latest research provided an evidence implicating OPRD1 SNPs (rs2236857 and 
rs581111) in liability for heroin dependence (Nelson et al., 2014). In another study, the 
opioid substance dependence among European American observed significant opioid 
dependence risk associated with rs1042114, a coding SNP in OPRD1, but not with other 
OPRD1 SNPs. Another investigation (Levran et al., 2008a) that had a larger sample of 
heroin dependent cases reported a putative association with three SNPs in OPRD1. The 
haplotype association study among African American between rs1042114 and 
rs2234918 also showed a nominally significant association with opioid and cocaine 
addiction (Crist et al., 2013b). In association and family study of OPRD1 with drug 
dependence, Franke and colleagues failed to find an association for rs2234918 among 
the German origins (Franke et al., 1999). 
 
 Similarly, a recent research conducted for SNP rs2236861 showed a significant 
association with drug addiction with control group compared to drug dependents 
(Randesi et al., 2016). Although earlier research showed significant association with 
drug dependence (Levran et al., 2008a, Beer et al., 2013). There was also no significant 
evidence for the role of variant rs1042114 among subjects from China, the G  allele was 
totally absent from both substance dependent and control subjects (Xu et al., 2002). This 
report supported by another study, which showed no significant association with drug 
dependence among the Chinese population (Xuei et al., 2007). In this current study, we 
will be able to provide data on the minor allele G in Malaysian population, the absence 
of variant G will confirm the non-existence of the variant among the Asian population.  
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1.4.3 PDYN 
The human prodynorphin gene (PDYN) is located at chromosome 20. It consists 
of four exons, exon 1 and exon 2 contain the 5′-untranslated region, exon 3 encodes a 
signal peptide, and exon 4 encodes dynorphin peptides, including α-neoendorphin, β-
neoendorphin, dynorphin A and dynorphin B (Cox, 1982, Nikoshkov et al., 2005). 
Dynorphin peptides and prodynorphin mRNA are particularly abundant in the nucleus 
accumbens, caudate, amygdala, hippocampus, and hypothalamus (Mansour et al., 1994, 
Hurd, 1996, Akil et al., 1998).  
 
  PDYN precursor (Schwarzer, 2009), bind to all three opiate receptors, but it 
shows a preference for the kappa opioid receptor. Dynorphins are believed to mediate 
the aversive effects of drugs of abuse as experimental administration of KOR agonists in 
animals produces place aversion (Mucha & Herz, 1986, Shippenberg & Herz, 1986, 
Land et al., 2008, Chartoff et al., 2012, Koob, 2017) and dysphoria (Shippenberg et al., 
2007). This is believed to be due, in part, to a reduction in dopaminergic 
neurotransmission on KOR stimulation and increased PDYN gene expression (Nestler, 
2004). Exposure to cocaine upregulates dynorphin immunoreactivity in the brain regions 
in the caudate and ventral palladium (Hurd & Herkenham, 1995, Staley et al., 1997), it is 
noted that a chronic exposure to heroin increases PDYN mRNA in the central amygdala 
and nucleus accumbens shell (Solecki et al., 2009). A Naloxone-precipitated withdrawal 
was found to accentuate the increase in morphine-induced dynorphin expression in the 
striatum and accumbens in rats (Nylander et al., 1995). Such studies have led researchers 
to hypothesize that dynorphin may contribute to the negative emotional states 
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experienced during withdrawal from drugs of abuse and motivate continued drug use as 
a consequence of negative reinforcement (Koob & Le Moal, 2008, Wee & Koob, 2010).  
 
Variants of the prodynorphin gene have been studied in addiction for opiates, 
cocaine, and alcohol, as well as in in vitro functional studies. Many of the variants in the 
PDYN were associated with increased risk for drug addiction (Ray et al., 2005, 
Nikoshkov et al., 2008). In China, it was reported that rs35286281, rs1022563, 
rs2235749 and rs910080 associated with heroin addicts (Wei et al., 2011) and in the 
United States the researchers identified an increased risk of developing opioid 
dependence in the female for the SNP rs1022563 (Clarke et al., 2009). Another study 
that was conducted by a similar group and the findings showed that the OR for 
rs910080, rs199774 and rs1022563 were increased in the female opioid dependent 
among European Americans; however there was no association for female African 
American population (Clarke, 2012). In another association study, rs910080 was 
associated with cocaine addiction among European American and African American 
(Yuferov et al., 2009). The results show that there is a difference in the genetic profile 
between male and female. Future studies should be focusing on both genders; such 
differences have implication on drug dependence recovery therapy.  
 
1.4.4 COMT  
 The catechol-O-methyltransferase (COMT) enzyme metabolizes the 
catecholamines dopamine, epinephrine and norepinephrine, and is a key modulator of 
dopaminergic and adrenergic neurotransmission. Catechol-O-methyltransferase (COMT) 
plays a major role in brain catecholamine metabolism by catalyzing the transfer of a 
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methyl group from S-adenosyl-methionine (SAM) to catecholamines (Chen et al., 2004). 
COMT is in the chromosome 22q11.21–q11.23, it is frequently included in the 
velocardiofacial syndrome (VCFS) deletion region (Grossman et al., 1992). Numerous 
genetic associations have been reported for several SNPs or haplotypes at the COMT 
locus. These include VCFS-related traits (Lachman et al., 1996, Shifman et al., 2002, 
Bearden et al., 2004, Gothelf et al., 2005), schizophrenia (Lachman et al., 1996, Shifman 
et al., 2002), anxiety-related personality traits (Stein et al., 2005), pain sensitivity 
(Diatchenko et al., 2005, Nackley et al., 2006), psychological stress response (Jabbi et 
al., 2007), and nicotine dependence (Beuten et al., 2006). 
 
Variant rs737866 SNP was associated with cocaine and heroin addiction, 
haplotype association between AAT of rs737866, rs4680 and rs174696 were conducted 
among European American and African American, this haplotype was significantly 
associated with cocaine in this two populations. It was concluded that the association 
was due to its role in the metabolism of dopamine and norepinephrine, cocaine interferes 
the process between dopamine and the receptor by binding to it which is the reward 
pathway for drug dependence (Ittiwut et al., 2011, Baik, 2013). Another study in China 
with heroin dependents proved that TT genotype of rs737866 has a higher association 
with addiction compared to CT and CC. It is noted that individuals with COMT variant 
gene increase the enzymatic activity with substance abuse. They may experience long 
lasting excitement and may increase the severity of drug dependence. However, in this 
study, wild type genotype TT was associated with heroin; it is noted in this report that 
study was not compared with control group, which might be the limitation (Li et al., 
2011). 
